These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31077072)

  • 1. Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials.
    Vetter ML; Johnsson K; Hardy E; Wang H; Iqbal N
    Diabetes Ther; 2019 Aug; 10(4):1249-1270. PubMed ID: 31077072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
    MacConell L; Gurney K; Malloy J; Zhou M; Kolterman O
    Diabetes Metab Syndr Obes; 2015; 8():241-53. PubMed ID: 26056482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
    Marso SP; Hardy E; Han J; Wang H; Chilton RJ
    Diabetes Ther; 2018 Apr; 9(2):551-564. PubMed ID: 29397532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.
    Macconell L; Brown C; Gurney K; Han J
    Diabetes Metab Syndr Obes; 2012; 5():29-41. PubMed ID: 22375098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.
    Inaishi J; Saisho Y
    Clin Pharmacol; 2022; 14():19-26. PubMed ID: 35422660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
    Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
    Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ
    Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
    Fineman MS; Mace KF; Diamant M; Darsow T; Cirincione BB; Booker Porter TK; Kinninger LA; Trautmann ME
    Diabetes Obes Metab; 2012 Jun; 14(6):546-54. PubMed ID: 22236356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
    Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
    Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.
    Seewoodhary J; Griffin L; Bain SC
    Diabetes Metab Syndr Obes; 2010 May; 3():165-72. PubMed ID: 21437086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis.
    Li X; Zhang Z; Duke J
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):234-9. PubMed ID: 24741695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
    Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
    Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives.
    Deng W; Qiu S; Yang G; Chen B
    Ther Clin Risk Manag; 2015; 11():1153-62. PubMed ID: 26309403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.